Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has demonstrated efficacy in the treatment of refractory and relapsed B cell lymphomas, with complete response (CR) rates ranging from 39% to 88% [1–5]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.